Chapter 27: Macrolides & Advanced Antibiotic Classes

Macrolides & Advanced Antibiotic Classes agents are characterized as broad-spectrum antibiotics effective against respiratory, gastrointestinal, and skin infections, as well as mycoplasmal pneumonia and Legionnaires’ disease. Significant attention is paid to pharmacokinetic considerations, such as the potential for hepatotoxicity, the necessity of slow intravenous administration to prevent phlebitis, and critical drug interactions involving warfarin and theophylline. The text then transitions to oxazolidinones like linezolid and tedizolid, which are vital for treating methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF); however, clinical caution is advised regarding the risk of serotonin syndrome when these drugs are combined with SSRIs or MAOIs. The chapter further explores lincosamides, specifically clindamycin and lincomycin, emphasizing their utility against anaerobes and the serious adverse reaction of Clostridium difficile-associated diarrhea (CDAD), also known as pseudomembranous colitis. A major section is dedicated to glycopeptides, particularly vancomycin, which inhibits cell wall synthesis and is used for severe infections including MRSA and C. difficile (oral route); this section details the management of severe toxicities such as nephrotoxicity, ototoxicity, and Vancomycin Flushing Syndrome (formerly Red Man Syndrome) caused by rapid infusion. Finally, the summary covers lipopeptides like daptomycin, which causes bacterial cell death via membrane depolarization, and highlights the specific risk of rhabdomyolysis, requiring close monitoring of creatine phosphokinase (CPK) levels, especially in patients concurrently taking statins.